Pharmacogenomics: Unlocking the human genome for better drug therapy

被引:206
作者
McLeod, HL [1 ]
Evans, WE
机构
[1] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA
[2] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA
[3] Univ Tennessee, Memphis, TN 38105 USA
关键词
drug response; metabolism; polymorphism; SNP;
D O I
10.1146/annurev.pharmtox.41.1.101
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There is great heterogeneity in the way humans respond to medications, often requiring empirical strategies to find the appropriate drug therapy for each patient (the "art" of medicine). Over the past 50 years, there has been great progress in understanding the molecular basis of drug action and in elucidating genetic determinants of disease pathogenesis and drug response. Pharmacogenomics is the burgeoning field of investigation that aims to further elucidate the inherited nature of interindividual differences in drug disposition and effects, with the ultimate goal of providing a stronger scientific basis for selecting the optimal drug therapy and dosages for each patient. These genetic insights should also lead to mechanism-based approaches to the discovery and development of new medications. This review highlights the current status of work in this field and addresses strategies that hold promise for future advances in pharmacogenomics.
引用
收藏
页码:101 / 121
页数:23
相关论文
共 80 条
  • [1] MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
    Abbott, GW
    Sesti, F
    Splawski, I
    Buck, ME
    Lehmann, WH
    Timothy, KW
    Keating, MT
    Goldstein, SAN
    [J]. CELL, 1999, 97 (02) : 175 - 187
  • [2] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [3] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    Alizadeh, AA
    Eisen, MB
    Davis, RE
    Ma, C
    Lossos, IS
    Rosenwald, A
    Boldrick, JG
    Sabet, H
    Tran, T
    Yu, X
    Powell, JI
    Yang, LM
    Marti, GE
    Moore, T
    Hudson, J
    Lu, LS
    Lewis, DB
    Tibshirani, R
    Sherlock, G
    Chan, WC
    Greiner, TC
    Weisenburger, DD
    Armitage, JO
    Warnke, R
    Levy, R
    Wilson, W
    Grever, MR
    Byrd, JC
    Botstein, D
    Brown, PO
    Staudt, LM
    [J]. NATURE, 2000, 403 (6769) : 503 - 511
  • [4] Thiopurine methyltransferase alleles in British and Ghanaian populations
    Ameyaw, MM
    Collie-Duguid, ESR
    Powrie, RH
    Ofori-Adjei, D
    McLeod, HL
    [J]. HUMAN MOLECULAR GENETICS, 1999, 8 (02) : 367 - 370
  • [5] Pharmacogenetic prediction of clozapine response
    Arranz, MJ
    Munro, J
    Birkett, J
    Bolonna, A
    Mancama, D
    Sodhi, M
    Lesch, KP
    Meyer, JFW
    Sham, P
    Collier, DA
    Murray, RM
    Kerwin, RW
    [J]. LANCET, 2000, 355 (9215) : 1615 - 1616
  • [6] Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine
    Black, AJ
    McLeod, HL
    Capell, HA
    Powrie, RH
    Matowe, LK
    Pritchard, SC
    Collie-Duguid, ESR
    Reid, DM
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 129 (09) : 716 - 718
  • [7] The essence of SNPs
    Brookes, AJ
    [J]. GENE, 1999, 234 (02) : 177 - 186
  • [8] Chen XN, 1999, GENOME RES, V9, P492
  • [9] The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations
    Collie-Duguid, ESR
    Pritchard, SC
    Powrie, RH
    Sludden, J
    Collier, DA
    Li, T
    McLeod, HL
    [J]. PHARMACOGENETICS, 1999, 9 (01): : 37 - 42
  • [10] The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia
    Coulthard, SA
    Howell, C
    Robson, J
    Hall, AG
    [J]. BLOOD, 1998, 92 (08) : 2856 - 2862